RE:RE:New CEOJPkatz wrote:
That would be Sweet if true!! Only problem is so much damage has been done by Dan... Not sure if this can be salvaged at this point.
The way I look at it ... regardless of who was the CEO ... we never would have made it to P3 for chronic pain (we now know that).
- no lowest dose determined for chronic
- liver issues over extended use were unexpected
The above two items are key in discussing today's shares price. Try figuring out blame based on those items and I don't think any CEO could have managed the share price differently.
Regardless - I assume Dan isn't retiring until we get a first win (if we get a first win). That's when I see a potential retirement and a different CEO needed to move an H2S development company forward - all cashed up and ready to go. It's just simpler to assume it that way w.r.t. Dan.
Also, I still think Dan has more than 70% of the votes on his side.
Can this company be salvaged? I sure hope so. Acute has risk but it's a simpler path forward. We also need acute to talk about a chronic regimen. 2022 will be a busy year and critical in determining how resilent our H2S platform really is.
Is acute the faster way to market?
Are all avenues still in play and will acute lead to a better understanding of a chronic regimen?
If chronic just can't move forward - can we be the flare-up specialists?
I still think there are many ways to play chronic but that's just my personal opinion ...
For example - let's look at IBD for chronic conditions (instead of Chronic Pain for the moment) ... a different example but it's the same thought process I used for chronic pain.
If we have an IBD drug selected in early 2022 and we also have Mesalamine available ... surely there's different potential regimen's out there that allows us to supply bursts of active ingedient with H2S, straight active drug (Mesalamine without H2S) and sugar pills ... in some manner that allows for safer and effective ways to deal with chronic IBD. Maybe you don't even need straight Mesalamine in the regimen and it can be accomplished with varying doses of the new IBD drug. It's just a matter of finding the right regimen. Otherwise ... we only offer IBD in bursts to contend with flare-ups in crohn's and colitis.
Lots to determine and it's the CEO that needs to set the right path forward from here. Don't think he could have done anything to save chronic in it's present state. All a learning process and we have interesting ways to pivot.
IMO
Good Luck All !